Crescita Therapeutics Inc (CTX)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Crescita Therapeutics Inc (CTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013134
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月27日
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Crescita Therapeutics Inc (Crescita Therapeutics) develops products for the treatment of skin diseases and their symptoms. The company’s product portfolio includes over-the-counter and prescription products such as topical creams. It offers pliaglis, a local anesthetic cream for superficial dermatological and cosmetic procedures. Crescita Therapeutics along with Ferndale Laboratories, Inc. develops Mical (1) and Mical (2) for the therapeutic areas of psoriasis and dermatological skin treatment, respectively. Mical (1) is in Phase 1 clinical trials and and Mical (2) is in preclinical stage of development. The company develops products using drug delivery platform that include multiplexed molecular penetration enhancers (MMPE) and DuraPeel. Crescita Therapeutics is headquartered in Mississauga, Ontario, Canada.

Crescita Therapeutics Inc (CTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
INTEGA Skin Sciences Acquires Alyria Skincare Product Line from Sanofi Consumer Health for USD1.3 Million 10
Licensing Agreements 11
Taro Pharma Enters into Licensing Agreement with Crescita Therapeutics 11
Dermatological Contract Research Company Enters into Licensing Agreement with Crescita Therapeutics 12
Knight Therapeutics Enters into Licensing Agreement with INTEGA Skin Sciences 13
Debt Offering 14
Crescita Therapeutics Raises USD0.7 Million in Private Placement of 9% Convertible Debenture 14
Asset Transactions 15
Crescita Therapeutics Divests Manufacturing Facility in Germany 15
Acquisition 16
Knight Therapeutics Acquires 4% Stake in Crescita Therapeutics 16
Crescita Therapeutics Acquires Intega Skin Sciences for USD7.6 Million 17
Crescita Therapeutics Inc – Key Competitors 18
Crescita Therapeutics Inc – Key Employees 19
Crescita Therapeutics Inc – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Financial Announcements 21
Nov 10, 2017: Crescita Therapeutics Announces 2017 Third Quarter Results and Appoints New CFO 21
Aug 14, 2017: Crescita Therapeutics Announces Profitable 2017 Second Quarter Results 23
May 15, 2017: Crescita Therapeutics Announces 2017 First Quarter Results 25
Mar 30, 2017: Crescita Therapeutics Announces 2016 Fourth Quarter and Year-End Results 27
Nov 14, 2016: Crescita Therapeutics Announces 2016 Third Quarter Results 29
Jul 27, 2016: Crescita Therapeutics Announces 2016 Second Quarter Results 30
May 10, 2016: Crescita Therapeutics Announces 2016 First Quarter Results 32
Corporate Communications 34
Apr 12, 2017: Crescita Therapeutics Announces the Appointment of a New President 34
Feb 10, 2017: Crescita Therapeutics Announces Management and Board Changes 35
Nov 03, 2016: Crescita Appoints Dan Chicoine as Interim CEO 36
Sep 29, 2016: Crescita Therapeutics Announces Changes to the Board of Directors 37
Product News 38
Jan 26, 2017: Crescita Therapeutics Announces Launch of ISDIN Product Line at Brunet Pharmacy 38
Other Significant Developments 39
Mar 07, 2016: Crescita Therapeutics Provides Corporate Update 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Crescita Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Crescita Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
INTEGA Skin Sciences Acquires Alyria Skincare Product Line from Sanofi Consumer Health for USD1.3 Million 10
Taro Pharma Enters into Licensing Agreement with Crescita Therapeutics 11
Dermatological Contract Research Company Enters into Licensing Agreement with Crescita Therapeutics 12
Knight Therapeutics Enters into Licensing Agreement with INTEGA Skin Sciences 13
Crescita Therapeutics Raises USD0.7 Million in Private Placement of 9% Convertible Debenture 14
Crescita Therapeutics Divests Manufacturing Facility in Germany 15
Knight Therapeutics Acquires 4% Stake in Crescita Therapeutics 16
Crescita Therapeutics Acquires Intega Skin Sciences for USD7.6 Million 17
Crescita Therapeutics Inc, Key Competitors 18
Crescita Therapeutics Inc, Key Employees 19
Crescita Therapeutics Inc, Subsidiaries 20

★海外企業調査レポート[Crescita Therapeutics Inc (CTX)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • VeriSign Inc (VRSN):企業の戦略的SWOT分析
    VeriSign Inc (VRSN) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Checkpoint Therapeutics Inc (CKPT):製薬・医療:M&Aディール及び事業提携情報
    Summary Checkpoint Therapeutics Inc (Checkpoint Therapeutics), a subsidiary of Fortress Biotech Inc, is a clinical-stage biopharmaceutical company that acquires, develops and commercializes non-chemotherapy and immune enhanced combination treatments for the treatment of solid tumor cancers. The comp …
  • Ricerca Biosciences LLC-製薬・医療分野:企業M&A・提携分析
    Summary Ricerca Biosciences LLC (Ricerca), formerly Ricerca Inc, a subsidiary of Main Market Partners LLC, is a contract research organization that offers services to accelerate drug development. The organization's service portfolio includes drug safety and metabolism, chemical development, agrochem …
  • OPKO Health Inc (OPK):製薬・医療:M&Aディール及び事業提携情報
    Summary OPKO Health Inc (OPKO) discovers, develops, manufactures and commercializes novel diagnostic technologies and pharmaceuticals. The company’s product portfolio includes point-of-care tests, laboratory developed tests (LDTs), molecular diagnostics tests, and proprietary pharmaceuticals and vac …
  • Duke Realty Corporation:企業の戦略・SWOT・財務情報
    Duke Realty Corporation - Strategy, SWOT and Corporate Finance Report Summary Duke Realty Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Perfint Healthcare Pvt Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Perfint Healthcare Pvt Ltd (Perfint), formerly Perfint Engineering Services Pvt Ltd is a medical device company that develops image guided interventional products for onchology and pain care. The company’s products comprise MAXIO, stereotactic accessory to a computed tomography system; ROBIO …
  • Bonavista Energy Corp (BNP):企業の財務・戦略的SWOT分析
    Bonavista Energy Corp (BNP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • TMRC Co Ltd-製薬・医療分野:企業M&A・提携分析
    Summary TMRC Co Ltd (TMRC) is a biopharmaceutical company that develops and markets anti-cancer and cancer related products. The company’s products include tamibarotene Am-80, TOS-80T, OMS0728, and others. Its tamibarotene is a synthetic retinoid, which is designed to develop drug-able properties of …
  • Quality Systems Inc (QSII)-医療機器分野:企業M&A・提携分析
    Summary Quality Systems Inc (QSI) is a healthcare technology company that develops and markets practice management and electronic health records solutions. The company’s solutions comprise ambulatory solutions, population health management and analytics, RCM services, NextGen consulting services, in …
  • China Yurun Food Group Limited:企業の戦略・SWOT・財務情報
    China Yurun Food Group Limited - Strategy, SWOT and Corporate Finance Report Summary China Yurun Food Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Banco Hipotecario SA (BHIP3):企業の財務・戦略的SWOT分析
    Banco Hipotecario SA (BHIP3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Tethys Oil AB (TETY):企業の財務・戦略的SWOT分析
    Summary Tethys Oil AB (Tethys Oil) is an upstream oil and gas company that offers exploration, development and production of oil and natural gas reserves. The company holds 2P reserves of 21.4 mmbo and has an oil production of barrels from Blocks in Sultanate of Oman. It also holds onshore explorati …
  • Oncor Electric Delivery Company LLC:電力:M&Aディール及び事業提携情報
    Summary Oncor Electric Delivery Company LLC (Oncor) a subsidiary of NextEra Energy, Inc., is a regulated electricity transmission and distribution company that operates distribution and transmission systems. It provides transmission grid connections to merchant generation facilities and interconnect …
  • JX Nippon Oil & Energy Corporation-石油・ガス分野:企業M&A・提携分析
    Summary JX Nippon Oil & Energy Corporation (JXNOE) is a downstream refining company. The company refines and markets petroleum and petrochemical products. Its products include petrochemicals, lubricants, optical films, greases, fluids, engine oils, composites, Panaferd-AX, Tow PREPREG, sheet pallet …
  • Mustek Limited (MST):企業の財務・戦略的SWOT分析
    Mustek Limited (MST) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • GrabTaxi Holdings Pte Ltd:企業の戦略的SWOT分析
    GrabTaxi Holdings Pte Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Union Jack Oil plc (UJO):企業の財務・戦略的SWOT分析
    Summary Union Jack Oil Plc (Union Jack Oil), formerly Union Jack Oil Ltd is an onshore oil and gas company that offers exploration and development of hydrocarbon projects. The company develops its portfolio of oil and gas assets by acquiring interests in drill ready prospects. It holds license inter …
  • SK Chemicals Co Ltd (006120):製薬・医療:M&Aディール及び事業提携情報
    Summary SK Chemicals Co Ltd (SK Chemicals) is a chemical company that provides life sciences products and solutions. The company manufactures polyester and acetate yarns for textile, and industrial uses. Its copolyesters comprise ecozen, skygreen and skypets. SK Chemicals provides high-performance r …
  • Polski Koncern Naftowy Orlen SA (PKN):石油・ガス:M&Aディール及び事業提携情報
    Summary Polski Koncern Naftowy Orlen SA (PKN Orlen) is an integrated oil and gas company. It explores for and produces crude oil and natural gas; manufactures petroleum products; transports and sells crude oil and petroleum products; and markets natural gas and natural gas liquids. Its product portf …
  • Clayton Homes Inc:企業の戦略・SWOT・財務情報
    Clayton Homes Inc - Strategy, SWOT and Corporate Finance Report Summary Clayton Homes Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆